Research programme: anti-HAAH monoclonal antibodies - Panacea

Drug Profile

Research programme: anti-HAAH monoclonal antibodies - Panacea

Alternative Names: PAN 22; PAN-355; PAN-622

Latest Information Update: 18 Feb 2016

Price : $50

At a glance

  • Originator Massachusetts Institute of Technology
  • Developer Goodwin Biotechnology; Massachusetts Institute of Technology; Panacea Pharmaceuticals
  • Class Monoclonal antibodies; Radiopharmaceutical diagnostics
  • Mechanism of Action Aspartic acid 2-oxoglutarate-dependent dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Liver cancer

Most Recent Events

  • 01 Feb 2016 Panacea Pharmaceuticals and Goodwin Biotechnology collaborate to develop radiolabelled conjugates of anti-HAAH monoclonal antibody in USA for Cancer
  • 01 Feb 2016 Preclinical trials in Cancer (Diagnosis) in USA (Parenteral)
  • 10 Dec 2007 PAN 622 selected as lead cancer therapeutic product
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top